Skip to main content

Table 2 The translational application of autophagy activators in anticancer therapy by regulating EMT

From: Crosstalk between autophagy and epithelial-mesenchymal transition and its application in cancer therapy

Autophagy Activators Impair/Enhance EMT Mechanisms Cancer Types References
Rapamycin Impair Prohibiting TGF-β-induced EMT Gallbladder cancer (GBC) [27]
Rapamycin Impair Inhibiting depletion of FBXW7-induced EMT and stem cell-like behavior Colon cancer [146]
Rapamycin Impair Prohibiting TGF-β-induced EMT A cell culture model of TGF-β-induced EMT [147]
Brusatol Impair Decreasing expression of N-cadherin, Vimentin and up-regulating expression of E-cadherin Hepatocellular carcinoma (HCC) [148]
Combination of P38 inhibitor SB202190 and JUN inhibitor SP600125 Impair Inhibiting EMT markers expression Ovarian cancer [149]
Alisertib (ALS, MLN8237) Impair Regulating E-cadherin suppressor with the involvement of Sirt1 Osteosarcoma (OS) [150]
mTORC inhibitor AZD2014 Impair Down-regulating the expression of Snail and MMP2 Hepatocellular carcinoma (HCC) [151]
Metformin Impair Inhibit mTOR pathway and regulate expression of the EMT-related markers E-cadherin, N-cadherin, and Snail. Thyroid cancer [28]